intermediate stages for 2 years. Details of licenced capacity and production to the extent information is available, are given in the Annexure.

(b) and (c) Information is being collected and will be laid on the table of the House.

(d) No, Sir.

(e) Diosgenin and Solasodine are not banned for import under the Export and Import Policy.

(f) Does not arise.

Annexure

Sl. No.	Name of the Bulk drug/ Name of the company	Licens d Capacity	Production (Kgs.)		
			1982-83	1983-84	1984-85
I.	*BETAMETHASONE*				
	(i) Glaxo Labs.	425·00	583·00	613·88	712·64
	(ii) T.N. Dadha	20·00	5·41	..	20·20
II.	*DEXAMETHASONE*				
	(i) Merind	120·00	152·39	128·38	160·75
	(ii) Cadila Labs.	400·00	6·25	9·41	53·31
III.	*PREDENISOLONE*				
	Wyeth Labs.	1719·00	824·00	1,846·00	1,682·00

Anti-Leprosy Drugs

861. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) the names of the drugs being marketed for leprosy disease;

(b) how many of these drugs are being imported into the country;

(c) what is the present custom duty imposed on each drug and what is the mark up allowed on the formulations based on each drug according to Drugs Price Control Order, 1979;

(d) whether there are any other drugs for other indications for which lower mark ups, than this, are allowed, if so, what are the names of those drugs; and

(e) what are the reasons for allowing higher mark up for medicines used by leprosy patients?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) The major drugs used for treatment of Leprosy are Dapsone, Clofazimine, and Rifampicin.

(b) During the year 1984-85 there were no imports of Clofazimine, Dapsone was partially imported and Rifampicin was completely imported. Commencement of production of Rifampicin was recently reported.

(c) Customs duty on Dapsone is 90 per cent *ad-valorem* whereas Clofazimine and Rifampicin are levied nil rate of custom duty. Dapsone formulations are allowed a mark-up of 40 per cent on the ex-factory cost whereas the formulations based on the other two drugs are allowed a mark-up of upto 100 per cent on the ex-factory cost.

(d) Formulations specified under Category I and II of the Third Schedule to the Drugs (Prices Control) Order, 1979 are allowed a mark-up of 40 per cent and 55 per cent respectively on the ex-factory cost. Formulations falling under Category III of the Third Schedule are allowed a mark-up of upto 100 per cent.

(e) Mark-up on individual formulations is allowed in accordance with the provision of the 1978 Drug Policy and the Drugs (Prices Control) Order, 1979.

Drugs for anthelmintics indications

862. SHRI NAND KISHORE BHATT: Will the Minister of INDUSTRY be pleased to state:

(a) what are the drugs being produced in the country for the indications of anthelmintics;

(b) whether the finished medicines based on these drugs fall under price control or exempted from Price Control Order, 1979;

(c) in case, it falls under Price Control Order whether the inclusion is notified or it is automatic;

(d) whether any such drug was introduced after the announcement of Drugs Price Control Order, 1979;

(e) if so, whether those drugs were included; and

(f) if so, when and if not, the reasons thereof?

THE MINISTER OF STATE IN THE DEPARTMENT OF CHEMICALS AND PETROCHEMICALS (SHRI R. K. JAICHANDRA SINGH): (a) Names of Anthelmintics bulk drugs produced in the country are:

(1) Piperazine and its salts
(2) Bephenium Hydroxy Naphthoate
(3) Tetramisol
(4) Pyrentel Pamoate
(5) Mebendazole
(6) Fenbendazole

(b) and (c) Formulations based on the above drugs are price controlled.

(d) Fenbendazole and its formulations were introduced after the promulgation of Drugs (Price Control) Order, 1979.

(e) and (f) In reply to Rajya Sabha Unstarred Question No. 2310 answered on 19th August, 1985 it has already been explained that formulations based on Fenzendazole are price controlled. Based on the application of M/s. Moechst India Limited submitted under Drugs (Prices Control) Order, 1979, it was noticed that the indigenous price of Fenbendazole as communicated by them was not significantly different from the landed cost of imports. It was, therefore, decided not to list this bulk drug under Drug (Prices Control) Order, 1979.

Production of drugs by multinationals

863. SHRI MAHENDRA MOHAN MISHRA: Will the Minister of INDUSTRY be pleased to state:

(a) whether his attention has been drawn to the news item appeared in the Statesman dated 12th November, 1985 under the heading "MNCS lukewarm to new drug policy";

(b) whether it is a fact that multinational drug companies are not concentrating towards the production of bulk drugs;

(c) what was the production of bulk drugs during the last 3 years, yearwise in value of these companies;

(d) names of the multinational drug companies operating in India alongwith the drugs being manufactured by each of them from penultimate/intermediate stages and since when each drug is produced from these stages;

(e) whether it is a fact that they are mainly concentrating towards the manufacture of Tonics, Vitamin preparations, harmones, cough syrups, cough Logenzes and vaporabs; and